SCHEMBL6081148

SCHEMBL6081148

CC(C)(C)OC(=O)C(C)(C)Oc1ccc(O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.47
PPARA Q07869 8/20 0.46
CYP1A2 P05177 3/20 0.46
CYP3A4 P08684 3/20 0.46
TSHR P16473 3/20 0.46
ABCB11 O95342 2/20 0.46
HTR2A P28223 2/20 0.46
PMP22 Q01453 2/20 0.46
ELANE P08246 5/20 0.46
MAPT P10636 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2D6 P10635 1/20 0.44
PPARG P37231 4/20 0.42
LMNA P02545 3/20 0.41
CYP2C9 P11712 2/20 0.41
BLM P54132 2/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426828 0.84 PPARA (0.45) MEN1KMT2AALDH1A1PPARACYP1A2
SCHEMBL3435787 0.84 PPARA (0.45) MEN1KMT2AKDM4EALDH1A1PPARA
SCHEMBL23903398 0.84 PPARA (0.66) MEN1KMT2AALDH1A1PPARACYP1A2
SCHEMBL5727051 0.84 PPARA (0.45) MEN1KMT2APPARACYP1A2CYP3A4
SCHEMBL18804484 0.83 PPARA (0.46) MEN1KMT2AKDM4EALDH1A1PPARA
SCHEMBL4187063 0.83 MEN1 (0.50) MEN1KMT2AKDM4EALDH1A1PPARA
SCHEMBL977500 0.82 CA1 (0.48) MEN1KMT2AALDH1A1PPARACYP1A2
SCHEMBL318984 0.81 PPARG (0.68) MEN1KMT2APPARACYP1A2CYP3A4
SCHEMBL3585884 0.81 PPARA (0.48) MEN1KMT2AALDH1A1PPARACYP1A2
SCHEMBL6780983 0.81 ALDH1A1 (0.44) MEN1KMT2AALDH1A1PPARACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461183-B2 PPAR agonist compounds, preparation and uses GENFIT (FR) 2013-06-11 US disclosed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP disclosed
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES GENFIT (FR) 2011-08-11 US disclosed
US-20060079696-A1 Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses GENFIT (FR) 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES PPARD, PPARA, PPARG MEN1 4851/4885KMT2A 3347/4885KDM4E 3040/4885
US-20060079696-A1 Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses AADAC, NAT1, PARN MEN1 3321/4885KMT2A 954/4885KDM4E 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.